RBx 10558

Drug Profile

RBx 10558

Alternative Names: PPD-10558; RBx-10558

Latest Information Update: 07 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ranbaxy Laboratories
  • Developer Furiex Pharmaceuticals
  • Class Antihyperlipidaemics
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 08 Dec 2011 Discontinued - Phase-II for Hypercholesterolaemia in USA (PO)
  • 23 Mar 2011 Phase-IIb clinical trials in Hypercholesterolaemia (with history of statin-associated myalgia) in USA (PO)
  • 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top